Epidemiology of systemic sclerosis: Incidence, prevalence, survival, risk factors, malignancy, and environmental triggers

Current Opinion in Rheumatology

Volumn 24, Issue 2, 2012, Pages 165-170

  Barnes, Jammie ^a   Mayes, Maureen D ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

environment; epidemiology; incidence; prevalence; systemic sclerosis

Indexed keywords

BLEOMYCIN; CREATINE KINASE; CREATININE; GADOLINIUM; HLA DRB1 ANTIGEN; PENTAZOCINE; SILICON DIOXIDE; TRYPTOPHAN; VINYL CHLORIDE;

AFRICAN AMERICAN; ARGENTINA; CANCER MORTALITY; CARDIOVASCULAR DISEASE; CAUCASIAN; CIGARETTE SMOKING; COMORBIDITY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DISEASE FREE SURVIVAL; GASTROESOPHAGEAL REFLUX; HEMATOCRIT; HUMAN; INCIDENCE; INDIA; LUNG CANCER; LUNG FIBROSIS; MORTALITY; PNEUMONIA; PREVALENCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SILICOSIS; SYSTEMIC SCLEROSIS; TAIWAN;

AGE OF ONSET; FEMALE; HUMANS; INCIDENCE; MALE; PREVALENCE; RISK FACTORS; SCLERODERMA, SYSTEMIC; SEX FACTORS; SURVIVAL RATE;

EID: 84856929470     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32834ff2e8     Document Type: Review

References (37)

1. Bolster MB, Silver RS. Clinical features of systemic sclerosis. In: Hochberg MC, Silman AJ, Smolen JS, et al., editors. Rheumatology. 5th ed. Philadelphia: Mosby, Elsevier; 2011. pp. 1373-1386.
2. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol 1988; 15:202-205. PMID:3361530. (Pubitemid 18073738)
3. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980; 23:581-590. PMID: 7378088.
4. Steen VD, Oddis CV, Conte CG, et al. Incidence of systemic sclerosis in Allegheny County, Pennsylvania. A twenty-year study of hospital-diagnosed cases, 1963-1982. Arthritis Rheum 1997; 40:441-445; PMID: 9082931.
5. Maricq HR, Weinrich MC, Keil JE, et al. Prevalence of scleroderma spectrum disorders in the general population of South Carolina. Arthritis Rheum 1989; 32:998-1006. (Pubitemid 19218379)
6. Mayes MD, Lacey JV Jr., Beebe-Dimmer J, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003; 48:2246-2255. (Pubitemid 36959206)
7. Arnett FC, Howard RF, Tan F, et al. Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma: Association with an Amerindian HLA haplotype. Arthritis Rheum 1996; 39:1362-1370. (Pubitemid 26270096)
8. Bernatsky S, Joseph L, Pineau CA, et al. Scleroderma prevalence: Demographic variations in a population-based sample. Arthritis Rheum 2009; 61:400-404; PMID: 19248123.
9. Englert H, Small-McMahon J, Davis K, et al. Systemic sclerosis prevalence and mortality in Sydney 1974-88. Aust NZ J Med 1999; 29:42-50. (Pubitemid 29136656)
10. Chandran G, Smith M, Ahern MJ, Roberts-Thomson PJ. A study of scleroderma in South Australia: Prevalence, subset characteristics and nailfold capillaroscopy. Aust N Z J Med 1995; 25:688-694; PMID: 8770332. (Pubitemid 26022644)
11. Roberts-Thomson PJ, Jones M, Hakendorf P, et al. Scleroderma in South Australia: Epidemiological observations of possible pathogenic significance. Intern Med J 2001; 31:220-229; PMID: 11456035. (Pubitemid 32592649)
12. Roberts-Thomson PJ, Walker JG, Lu TY, et al. Scleroderma in South Australia: Further epidemiological observations supporting a stochastic explanation. Intern Med J 2006; 36:489-497. (Pubitemid 43990900)
13. Tamaki T, Mori S, Takehara K. Epidemiological study of patients with systemic sclerosis in Tokyo. Arch Dermatol Res 1991; 283:366-371.
14. Silman A, Jannini S, Symmons D, Bacon P. An epidemiological study of scleroderma in the West Midlands. Br J Rheumatol 1988; 27:286-290; PMID: 3261609.
15. Allcock RJ, Forrest I, Corris PA, et al. A study of the prevalence of systemic sclerosis in northeast England. Rheumatology (Oxford) 2004; 43:596-602. (Pubitemid 38628190)
16. Geirsson AJ, Steinsson K, Guthmundsson S, Sigurthsson V. Systemic sclerosis in Iceland: A nationwide epidemiological study. Ann Rheum Dis 1994; 53:502-505; PMID: 7944633. (Pubitemid 24256978)
17. Kaipiainen-Seppanen O, Aho K. Rare systemic rheumatic and connective tissue diseases in Finland. J Int Med 1996; 240:81-84. (Pubitemid 26298129)
18. Le Guern V, Mahr A, Mouthon L, et al. Prevalence of systemic sclerosis in a French multiethnic county. Rheumatology (Oxford) 2004; 43:1129-1137. (Pubitemid 39232818)
19. Alamanos Y, Tsifetaki N, Voulgari PV, et al. Epidemiology of systemic sclerosis in northwest Greece 1981-2002. Semin Arthritis Rheum 2005; 34:714-720.
20. Arias-Nuñez MC, Llorca J, Vazquez-Rodriguez TR, et al. Systemic sclerosis in northwestern Spain: A 19-year epidemiologic study. Medicine (Baltimore) 2008; 87:272-280; PMID: 18794710.
21. Monaco AL, Bruschi M, Corte RL, et al. Epidemiology of systemic sclerosis in a district of northern Italy. Clin Exp Rheumatol 2011; 29 (Suppl. 65):S10-S14; PMID: 21586212. This study further supports the prevalence and incidence in European countries and continues the geographic trend.
22. Rosa JE, Soriano ER, Narvaez-Ponce L, et al. Incidence and prevalence of systemic sclerosis in a healthcare plan in Buenos Aires. J Clin Rheumatol 2011; 17:59-63; PMID: 21325964. This adds to the literatures of incidence and prevalence in Latin American countries and is important because it has not been reported on until this year.
23. Kuo CF, See LC, Yu KH, et al. Epidemiology and mortality of systemic sclerosis: A nationwide population study in Taiwan. Scand J Rheumatol 2011; 40:373-378. This is the first reported population study for systemic sclerosis and follows the trends previously reported in Japan.
24. Minz RW, Kumar Y, Amand S, et al. Antinuclear antibody positive antibody disorders in North India: An appraisal. Rheumatol Int 2011. PMID: 21898056 [Epub ahead of print]. India has not been represented in an epidemiology study for autoimmune diseases and this helps to show the incidence and prevalence of ANA-positive patients.
25. Steen VD, Medsger TA. Changes in the causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007; 66:940-944. (Pubitemid 46999798)
26. Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: A study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69:1809-1815. This article furthers the understanding of risk factors and the cause of death.
27. Hissaria P, Lester S, Hakendorf P, et al. Survival in scleroderma: Results from the population-based South Australian Register. InternMed J 2011; 41:381-390. This reproduces data about the mortality of scleroderma renal crisis and the influence of sex, age, and race.
28. Chaudhary P, Chen X, Assassi S, et al. Cigarette smoking is not a risk factor for systemic sclerosis. JT Arthritis Rheum 2011; 63:3098-3102. This study found that smoking is not a risk factor but that it may lead to worse disease. This study found that smoking is not a risk factor but that it may lead to worse disease.
29. Makol A, Reilly MJ, Rosenman KD. Prevalence of connective tissue disease in silicosis (1985-2006): A report from the state of Michigan surveillance system for silicosis. Am J Ind Med 2011; 54:255-262.
30. McCormic ZD, Khuder SS, Aryal BK, et al. Occupational silica exposure as a risk factor for scleroderma: A meta-Analysis. Int Arch Occup Environ Health 2010; 83:763-769.
31. Lipworth L, Holmich LR, McLaughlin JK. Silicone breast implants and connective tissue disease: No association. Semin Immunopathol 2011; 33:287-294.
32. Nashid M, Khanna PP, Furst DE,et al.; investigators of the D-penicillamine, human recombinant relaxin and oral bovine type I collagen clinical trials. Gender and ethnicity differences in patients with diffuse systemic sclerosis: Analysis from three large randomized clinical trials. Rheumatology (Oxford) 2011; 50: 335-342. Contribution to the known literature, SSc and the disease being worse in African-American patients. 33.
33. Manno RL, Wigley FM, Gelber AC, Hummers LK. Late-Age onset systemic sclerosis. J Rheumatol 2011; 38:1317-1325. Their findings suggested that the older patients with SSc had an increased risk for pulmonary hypertension, renal impairment, cardiac disease, and muscle weakness
34. Nguyen B, Mayes MD, Arnett FC, et al. HLA-DRB1-0407 and-1304 are risk factors for scleroderma renal crisis. Arthritis Rheum 2011; 63:530-534.
35. Gorlova O, Martin JE, Rueda B, et al. Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genomewide association strategy. PLoS Genet 2011; 7:E1002178. They found that disease susceptibility as well as disease severity is influenced by genetic factors including both the HLA/MHC region as well as non-MHC loci.
36. Siau K, Laversuch CJ, Creamer P, O'Rourke KP. Malignancy in scleroderma patients from south west England: A population-based cohort study. Rheumatol Int 2011; 31:641-645. This adds to the literature about malignancy and SSc and there continues to be conflicting results on the types of increased malignancy.
37. Olesen AB, Svaerke C, Farkas DK, Sørensen HT. Systemic sclerosis and the risk of cancer: A nationwide population-based cohort study. Br J Dermatol 2010; 163:800-806.